Intracellular receptors mediate the effects of lipophilic signaling molecules that can diffuse across the cell membrane, including steroid hormones, thyroid hormones, vitamin D, and retinoic acid. Unlike cell surface receptors that span the plasma membrane, these receptors reside in the cytoplasm or nucleus of target cells. The signaling mechanism involves direct regulation of gene transcription, producing slow but sustained biological effects through changes in protein synthesis.
Nuclear Receptor Superfamily
Intracellular receptors belong to the nuclear receptor superfamily, a large group of structurally related transcription factors that share characteristic functional domains. These receptors typically contain a highly conserved DNA-binding domain (DBD) with two zinc finger motifs that enable specific binding to DNA sequences, and a ligand-binding domain (LBD) in the C-terminal region that binds the hormone or drug. An N-terminal domain contains regions important for transcriptional activation and exhibits considerable variability among different receptors, allowing for receptor-specific interactions with co-regulatory proteins.
In the absence of ligand, many of these receptors exist in an inactive complex bound to heat shock proteins (HSPs), particularly the glucocorticoid receptor mineralocorticoid receptor, and androgen receptor. These chaperone proteins maintain the receptor in a conformation capable of binding ligand while preventing the receptor from entering the nucleus or binding DNA in the absence of hormone. When ligand binds to the ligand-binding domain, the receptor undergoes a conformational change that causes dissociation of the heat shock protein complex, exposing nuclear localization signals and allowing the receptor to bind DNA and regulate transcription.
Steroid Hormone Receptors
Steroid hormone receptors represent the best-characterized class of intracellular receptors. This group includes the glucocorticoid receptor (GR), mineralocorticoid receptor (MR), estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR). These receptors mediate the effects of glucocorticoids like cortisol, mineralocorticoids like aldosterone, and the sex steroids estradiol, progesterone, and testosterone.
The glucocorticoid receptor provides a paradigm for understanding steroid hormone action. In the absence of glucocorticoids, GR resides in the cytoplasm complexed with heat shock proteins including HSP90, HSP70, and others. When cortisol or the synthetic glucocorticoid dexamethasone binds, the receptor undergoes a conformational change that releases the heat shock proteins, allowing the receptor to homodimerize (form complexes of two identical receptor molecules). The activated receptor dimers translocate into the nucleus where they bind to specific DNA sequences called glucocorticoid response elements (GREs) located in the promoter regions of target genes.
Once bound to DNA, the activated receptor recruits co-activator complexes that modify chromatin structure and interact with the basal transcription machinery, either increasing or decreasing gene transcription depending on the specific gene and cellular context. Glucocorticoids exert their anti-inflammatory effects through multiple mechanisms including transactivation of anti-inflammatory genes and transrepression of pro-inflammatory genes through interactions with other transcription factors like NF-κB and AP-1. Synthetic glucocorticoids like prednisone and dexamethasone are among the most widely prescribed anti-inflammatory and immunosuppressive agents in clinical medicine.
Non-Steroid Intracellular Receptors
Several important intracellular receptors are not activated by steroid hormones but by other lipophilic molecules. The thyroid hormone receptor (TR), vitamin D receptor (VDR), and retinoic acid receptor (RAR) belong to a subclass of nuclear receptors that typically reside in the nucleus even in the absence of ligand, often bound to DNA as heterodimers with the retinoid X receptor (RXR). In the unliganded state, these receptors are typically associated with co-repressor complexes that actively repress transcription. Ligand binding induces a conformational change that releases co-repressors and allows recruitment of co-activators, switching the receptor from a transcriptional repressor to an activator.
Thyroid hormone receptors mediate the effects of triiodothyronine (T3), the biologically active form of thyroid hormone. These receptors play critical roles in regulating metabolic rate, growth, and development. The thyroid hormone receptor exists in several isoforms encoded by two separate genes (TRα and TRβ), with different tissue distributions and physiological functions. Thyromimetic drugs that selectively activate specific TR isoforms are being investigated for potential therapeutic applications including obesity and dyslipidemia, while anti-thyroid drugs like propylthiouracil and methimazole reduce thyroid hormone synthesis rather than acting directly on the receptor.
The vitamin D receptor (VDR) mediates the effects of calcitriol, the active form of vitamin D. Beyond its well-known role in calcium homeostasis and bone health, vitamin D signaling has been implicated in immune regulation, cell proliferation, and differentiation. Vitamin D analogs such as calcitriol and paricalcitol are used clinically to treat secondary hyperparathyroidism in chronic kidney disease, while the VDR ligand calcipotriene is used topically to treat psoriasis due to its ability to inhibit keratinocyte proliferation and promote differentiation.
Time Course and Clinical Implications
A defining characteristic of intracellular receptor signaling is its relatively slow time course compared to cell surface receptor signaling. Because these receptors act by regulating gene transcription and new protein synthesis, measurable biological effects typically require hours to days to develop. For example, the anti-inflammatory effects of glucocorticoids begin hours after administration and peak over days, reflecting the time required for changes in gene expression and protein levels. Similarly, the full therapeutic effects of selective estrogen receptor modulators (SERMs) like tamoxifen in breast cancer treatment require weeks to months of therapy.
This slow onset is balanced by prolonged duration of action, as the effects persist until the newly synthesized proteins are degraded and receptor levels return to baseline. The selective estrogen receptor modulators illustrate an important concept in intracellular receptor pharmacology—tissue-specific agonist or antagonist activity. Tamoxifen acts as an estrogen antagonist in breast tissue (making it useful for treating estrogen receptor-positive breast cancer) but as a partial agonist in bone and endometrium. Raloxifene, another SERM, acts as an agonist in bone but an antagonist in both breast and endometrium, making it useful for osteoporosis treatment with reduced breast cancer risk but without the increased endometrial cancer risk seen with tamoxifen. This tissue-specific activity reflects differential expression of co-activator and co-repressor proteins in different tissues, allowing for the development of therapeutically selective agents despite acting through a single receptor type.
